FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078495330> ?p ?o ?g. }

• W2078495330 endingPage "18" @default.
• W2078495330 startingPage "7" @default.
• W2078495330 abstract "To date, UCM707, (5Z,8Z,11Z,14Z)-N-(3-furylmethyl)eicosa-5,8,11,14-tetraenamide, has the highest potency and selectivity in vitro and in vivo as inhibitor of the endocannabinoid uptake. This may enable this compound to potentiate endocannabinoid transmission, with minimal side effects, in the treatment of several neurological disorders. In the present study, we examined whether the treatment with UCM707 produced beneficial effects, as other cannabinoid-related compounds have already shown, to alleviate motor deterioration or to delay/arrest neurodegeneration, in several models of neurological diseases such as Huntington's disease (HD), Parkinson's disease (PD) and multiple sclerosis (MS). UCM707 exhibited a notable anti-hyperkinetic activity in a rat model of HD generated by bilateral intrastriatal application of 3-nitropropionic acid. This effect was possibly associated with an amelioration of GABA and glutamate deficits induced by the toxin in the globus pallidus and the substantia nigra, respectively. However, UCM707 did not protect against the death of GABAergic neurons that occurs in rats with striatal atrophy generated by unilateral application of malonate, another animal model of HD, which is more useful to test neuroprotective strategies. In addition, UCM707 did not provide neuroprotection in rats with unilateral lesions of the nigrostriatal dopaminergic neurons caused by 6-hydroxydopamine, a rat model of PD. This was possibly due to the fact that UCM707 is devoid of anti-oxidant properties since another uptake inhibitor, AM404, that has these properties acted as a protective agent. Lastly, UCM707 was also unable to inhibit the development of the neurological impairment of rats with experimental autoimmune encephalomyelitis (EAE), an acute model of MS. However, UCM707, like other endocannabinoid uptake inhibitors reported previously, significantly reduced spasticity of the hindlimbs in a chronic relapsing EAE mice, a chronic model of MS. In summary, UCM707 might be a promising compound in HD to alleviate motor symptoms, which represents an important goal considering the current lack of efficient pharmacological treatments in this basal ganglia disorder. However, the compound was unable to delay neurodegeneration in this disorder and also in PD. In addition, UCM707 did not produce any neurological recovery from inflammatory attack in an EAE rat model of MS, although it retained the classic anti-spastic action shown by other uptake inhibitors in the EAE mouse model of this disease." @default.
• W2078495330 created "2016-06-24" @default.
• W2078495330 creator A5002926136 @default.
• W2078495330 creator A5016912802 @default.
• W2078495330 creator A5036189795 @default.
• W2078495330 creator A5043016138 @default.
• W2078495330 creator A5069868485 @default.
• W2078495330 creator A5078740675 @default.
• W2078495330 creator A5084677557 @default.
• W2078495330 creator A5086639238 @default.
• W2078495330 date "2006-01-01" @default.
• W2078495330 modified "2023-10-17" @default.
• W2078495330 title "UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders" @default.
• W2078495330 cites W1579877956 @default.
• W2078495330 cites W1775749144 @default.
• W2078495330 cites W1967558194 @default.
• W2078495330 cites W1969242791 @default.
• W2078495330 cites W1973295005 @default.
• W2078495330 cites W1977127465 @default.
• W2078495330 cites W1978211805 @default.
• W2078495330 cites W1981876620 @default.
• W2078495330 cites W1983729920 @default.
• W2078495330 cites W1989021659 @default.
• W2078495330 cites W1992606412 @default.
• W2078495330 cites W2002062235 @default.
• W2078495330 cites W2005828463 @default.
• W2078495330 cites W2006058223 @default.
• W2078495330 cites W2010665440 @default.
• W2078495330 cites W2011035933 @default.
• W2078495330 cites W2015987706 @default.
• W2078495330 cites W2016083532 @default.
• W2078495330 cites W2021950684 @default.
• W2078495330 cites W2024122340 @default.
• W2078495330 cites W2027300306 @default.
• W2078495330 cites W2028904201 @default.
• W2078495330 cites W2029009212 @default.
• W2078495330 cites W2029651427 @default.
• W2078495330 cites W2031888213 @default.
• W2078495330 cites W2034196069 @default.
• W2078495330 cites W2042196312 @default.
• W2078495330 cites W2052988246 @default.
• W2078495330 cites W2053910424 @default.
• W2078495330 cites W2056696760 @default.
• W2078495330 cites W2069460649 @default.
• W2078495330 cites W2072730289 @default.
• W2078495330 cites W2077091868 @default.
• W2078495330 cites W2095290615 @default.
• W2078495330 cites W2102941373 @default.
• W2078495330 cites W2104064731 @default.
• W2078495330 cites W2110514788 @default.
• W2078495330 cites W2113319670 @default.
• W2078495330 cites W2114728052 @default.
• W2078495330 cites W2118835279 @default.
• W2078495330 cites W2133702956 @default.
• W2078495330 cites W2137837192 @default.
• W2078495330 cites W2139196178 @default.
• W2078495330 cites W2161954110 @default.
• W2078495330 cites W2168882723 @default.
• W2078495330 cites W2171143812 @default.
• W2078495330 cites W2171637070 @default.
• W2078495330 cites W37724093 @default.
• W2078495330 cites W4252912293 @default.
• W2078495330 doi "https://doi.org/10.1016/j.euroneuro.2005.06.001" @default.
• W2078495330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16006105" @default.
• W2078495330 hasPublicationYear "2006" @default.
• W2078495330 type Work @default.
• W2078495330 sameAs 2078495330 @default.
• W2078495330 citedByCount "74" @default.
• W2078495330 countsByYear W20784953302012 @default.
• W2078495330 countsByYear W20784953302014 @default.
• W2078495330 countsByYear W20784953302015 @default.
• W2078495330 countsByYear W20784953302016 @default.
• W2078495330 countsByYear W20784953302017 @default.
• W2078495330 countsByYear W20784953302018 @default.
• W2078495330 countsByYear W20784953302019 @default.
• W2078495330 countsByYear W20784953302020 @default.
• W2078495330 countsByYear W20784953302021 @default.
• W2078495330 countsByYear W20784953302022 @default.
• W2078495330 countsByYear W20784953302023 @default.
• W2078495330 crossrefType "journal-article" @default.
• W2078495330 hasAuthorship W2078495330A5002926136 @default.
• W2078495330 hasAuthorship W2078495330A5016912802 @default.
• W2078495330 hasAuthorship W2078495330A5036189795 @default.
• W2078495330 hasAuthorship W2078495330A5043016138 @default.
• W2078495330 hasAuthorship W2078495330A5069868485 @default.
• W2078495330 hasAuthorship W2078495330A5078740675 @default.
• W2078495330 hasAuthorship W2078495330A5084677557 @default.
• W2078495330 hasAuthorship W2078495330A5086639238 @default.
• W2078495330 hasConcept C126322002 @default.
• W2078495330 hasConcept C137183658 @default.
• W2078495330 hasConcept C169760540 @default.
• W2078495330 hasConcept C170493617 @default.
• W2078495330 hasConcept C25498285 @default.
• W2078495330 hasConcept C2776925932 @default.
• W2078495330 hasConcept C2778187257 @default.
• W2078495330 hasConcept C2778559928 @default.
• W2078495330 hasConcept C2779134260 @default.
• W2078495330 hasConcept C2780278869 @default.

• next